Effects of Pelargonium sidoides extract on chemokine levels in nasal secretions of patients with non-purulent acute rhinosinusitis. (1st January 2020)

• Record Type: Journal Article
• Authors: Perić, Aleksandar; Vezmar Kovačević, Sandra; Barać, Aleksandra; Gaćeša, Dejan; Perić, Aneta V.; Vojvodić, Danilo
• Is Part Of: Journal of drug assessment. Volume 9(2020)Supplement 1
• Page Start: 145
• Page End: 150
• Publication Date: 2020-01-01
• Subjects: Cytokines -- inflammation -- nasal mucosa -- plants -- medicinal -- rhinitis -- sinusitis; Drugs -- Testing -- Periodicals; 615.1901
• DOI: 10.1080/21556660.2020.1838176
• Languages: English
• ISSNs: 2155-6660

Abstract

Abstract: Objective: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for improvement of the symptoms of uncomplicated upper airway inflammations, due to its antimicrobial and immunomodulatory actions. The aim of this investigation was to evaluate the effects of EPs 7630 on chemokine production in nasal mucosa and clinical parameters of patients with acute postviral rhinosinusitis (APRS). Methods: Twenty-six ( n = 26) APRS patients and 25 ( n = 25) control subjects were included in this prospective study. We measured the concentrations of thirteen chemokines in nasal secretions of APRS patients and controls by flow cytometry. The patients with APRS were treated by EPs 7630 20 mg oral tablets, three times daily for 10 days. We compared the chemokine levels in nasal secretions, nasal symptoms and endoscopic findings in patients, before and after therapy. Results: We found higher Total Symptom Score (TSS) and higher concentrations of MCP-1, MIP-1α, MIP-1β, MIP-3α, ENA-78 and IL-8 in nasal secretions of APRS patients than in controls. After therapy by EPs 7630, we found significant improvement in all symptoms and endoscopic findings of APRS. The concentrations of MCP-1, IP-10 and MIP-1β were significantly increased and levels of MIP-1α, ENA-78, GROα and IL-8 significantly decreased in nasal fluid samples after therapy. No adverse effects were reported during the treatment. Conclusion: Our results suggest the presence of modulatory effects of EPs 7630 on production of chemokines regulating the function of neutrophils and monocytes in the site of inflammation of the nasal mucosa in patients with APRS.